secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001714899-26-000030
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Therapeutics receives FDA approval for AVLAYAH in Hunter syndrome
------------------------------------------------------------------------

- FDA grants accelerated approval for AVLAYAH (tividenofusp alfa) to treat neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients ≥5 kg.
- First FDA-approved biologic designed to cross the blood-brain barrier using TransportVehicle platform.
- Approval based on 91% reduction in CSF heparan sulfate biomarker at week 24; 93% of patients reached normal range.
- Most common adverse reaction: infusion-related reactions; continued approval contingent on confirmatory COMPASS trial.
- FDA awarded Rare Pediatric Disease Priority Review Voucher (PRV) in connection with approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489926000030/0001714899-26-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489926000030/dnli-20260325.htm
  HTML page:      https://secwatch.observer/filing/0001714899-26-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer